XClose

UCL School of Pharmacy

Menu

3D printers from UCL spinout used for production of tailored medicines in leading cancer hospital

15 April 2025

A press release by Gustave Roussy Cancer Hospital in Paris, Europe’s leading cancer research hospital, has highlighted how the 3D printers developed by FABRX, a UCL School of Pharmacy spinout, are now routinely being used in their pharmacy department for production of more tailor

Picture of the M3DIMAKER2 GMP certified pharmaceutical 3D printer developed by FABRX for the production of personalised medicines. Gustave Roussy Cancer Hospital has acquired two of these printers for use in their clinical pharmacy department.

Gustave Roussy Cancer Hospital recently received their second M3DIMAKER2 pharmaceutical 3D printer for use in their clinical pharmacy department. A press release from the hospital has highlighted how both 3D printers are now routinely being used to produce personalised medicines to treat the hospital’s cancer patients.

The M3DIMAKER2 is the second generation, GMP certified pharmaceutical 3D printer developed by the company FABRX where multiple printheads can be activated at the same time, resulting in high versatility of the technology. FABRX span out from the Basit Research Group in UCL School of Pharmacy and the group remains at the forefront of translating research on 3D printing of personalised medicines into real-world impact.